Practical aspects of diagnosis and treatment of thrombotic thrombocytopenic purpura
Abstract
Thrombotic thrombocytopenic purpura (TTP) is characterized by a triad of symptoms: thrombocytopenia, hemolytic anemia and organ dysfunction due to disturbed microcirculation. TTP is caused by severe deficiency of a plasma metalloprotease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs 13) either due to congenital defects in the ADAMTS13 gene (congenital TTP) or development of autoantiobodies against ADAMTS13 (acquired TTP). Organ dysfunction is life threatening and may lead to death unless patients are immediately applied a therapy of plasma exchange (PEX). Initial diagnosis of TTP is based on clinical symptoms of ischemic organ injury, thrombocytopenia and hemolytic anemia with negative Coombs test and schistocytes in blood smear. Suspected TTP requires collection of pretreatment samples for measurement of ADAMTS3 activity and level of anti-ADAMTS13 autoantibodies. PEX should be initiated as soon as possible, even before the results of ADAMTS13 activity and anti-ADAMTS13 autoantibodies become available. ADAMTS13 activity below 5–10% with the presence of ADAMTS13 autoantibodies confirms the diagnosis of acquired TTP and daily PEX in combination with immunosuppressive treatment (corticosteroids) should be continued. Diagnosis of congenital TTP is confirmed by low ADAMTS13 activity in the absence of autoantibodies to ADAMTS13. Congenital TTP is usually treated with infusions of fresh frozen plasma to substitute the missing enzyme.
Keywords: thrombotic thrombocytopenic purpuraADAMTS13Upshaw-Schulman syndromeschistocytesplasma exchangeimmunosuppression
References
- Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost. 2014; 40(4): 493–502.
- Tsai HM. Thrombotic thrombocytopenic purpura, hemolytic-ure¬mic syndrome and related disorders. In: Greer JP, Foerster JM, Rodgers G. et. al. ed. Wintrobe’s clinical hematology, 13th edition. Wolters Kluwer, Lippincott, Williams and Wilkins, Philadelphia : 1077–1094.
- Scully M, Hunt BJ, Benjamin S, et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3): 323–335.
- Scully M, Cataland S, Coppo P, et al. International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017; 15(2): 312–322.
- Mansouri Taleghani M, von Krogh AS, Fujimura Y, et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie. 2013; 33(2): 138–143.
- Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005; 3(8): 1663–1675.
- Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013; 163(4): 514–519.
- Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010; 8(4): 631–640.
- Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010; 91(1): 1–19.
- Hassenpflug WA, Budde U, Schneppenheim S, et al. Inherited thrombotic thrombocytopenic purpura in children. Semin Thromb Hemost. 2014; 40(4): 487–492.
- George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371(7): 654–666.
- Savignano C, Rinaldi C, De Angelis V. Pregnancy associated thrombotic thrombocytopenic purpura: Practical issues for patient management. Transfus Apher Sci. 2015; 53(3): 262–268.
- Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015; 189: 68–72.
- Knöbl PN. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie. 2013; 33(2): 149–159.
- Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014; 5: 15–23.
- Coppo P. French Reference Center for Thrombotic Microangiopathies. Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Transfus Apher Sci. 2017; 56(1): 52–56.
- Kessler CS, Khan BA, Lai-Miller K. Thrombotic thrombocytopenic purpura: a hematological emergency. J Emerg Med. 2012; 43(3): 538–544.
- Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015; 125(25): 3860–3867.
- Cataland SR, Wu HM. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use. J Thromb Haemost. 2015; 13 Suppl 1: S223–S229.
- Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016; 173(5): 779–785.
- Kremer Hovinga JA, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2012; 2012: 610–616.
- Kopić A, Benamara K, Piskernik C, et al. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016; 14(7): 1410–1419.
- Scully M, Knöbl P, Kentouchem K, et al. Blood. Pharmacodynamic profile of a recombinant ADAMTS13 (BAX930) in hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman Syn¬drome (USS)). 2016; 128: 135.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)